Validation of business opportunities for a novel technology in pharmaceutical drug and vaccine discovery.
| Reference number | |
| Coordinator | Stockholms universitet holding AB |
| Funding from Vinnova | SEK 1 995 099 |
| Project duration | January 2016 - March 2018 |
| Status | Completed |
Important results from the project
We´ve developed the Salipro® technology, which represents an entirely novel system to stabilize important drug targets and makes them accessible for drug discovery, antibody generation and vaccine development. The aim of the project is to verify the Salipro® technology in accordance to the need of selected key customers, to secure future financing and to develop a profitable business.
Expected long term effects
The overall aim of the project is to create a unique value proposition that lowers R&D costs/efforts for customers from the pharmaceutical industry while improving success rate for companies developing therapeutic drugs and vaccines. At the end of the project we intend to have established a clear plan to build future revenue streams, validated various market segments and set a plan for company expansion.
Approach and implementation
In the course of this project, we will determine and contact several key customers from various market segments, evaluate the respective market potential, perform technical verification studies and determine the most suitable business model for company growth.